Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.

Overview

authors

Collà Ruvolo, Claudia

Würnschimmel, Christoph

Shariat, Shahrokh
Saad, Fred
Tilki, Derya
Graefen, Markus
Kluth, Luis A
Briganti, Alberto
Mandel, Philipp
Montorsi, Francesco
Chun, Felix K H
Karakiewicz, Pierre I

publication date

December 1, 2023

published in

Prostate cancer and prostatic diseases Journal

Identity

PubMed Central ID

PMC10638077

Scopus Document Identifier

85149643148

Digital Object Identifier (DOI)

10.1038/s41391-023-00656-4

PubMed ID

36899091

Additional Document Info

volume

26

issue

4